Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy (Q36135251)

12 August 2017

1 reference

title

Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy (English)

1 reference

12 August 2017

anti-retroviral agent

0 references

0 references

1 reference

Jeffrey S Barrett

1

1 reference

12 August 2017

Line Labbé

series ordinal

2

1 reference

12 August 2017

Marc Pfister

series ordinal

3

1 reference

12 August 2017

1 January 2005

1 reference

Clinical Pharmacokinetics

12 August 2017

1 reference

12 August 2017

44

1 reference

12 August 2017

6

1 reference

12 August 2017

591-625

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544060-00003

12 August 2017

0 references

cites work

Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacokinetics of zidovudine in infants: a population analysis across studies

1 reference

12 December 2020

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

12 December 2020

Antiretroviral Therapy-associated Serious and Life-threatening Toxicities

1 reference

12 December 2020

Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo

1 reference

12 December 2020

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring

1 reference

12 December 2020

Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

1 reference

12 December 2020

Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy

1 reference

12 December 2020

Antiretroviral pharmacokinetics in the paediatric population: a review

1 reference

12 December 2020

The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain

1 reference

12 December 2020

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

12 December 2020

The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

1 reference

12 December 2020

New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule

1 reference

12 December 2020

The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis.

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Strategies for control of zidovudine concentrations in serum

1 reference

12 December 2020

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

1 reference

12 December 2020

HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era.

1 reference

12 December 2020

Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads

1 reference

12 December 2020

Therapeutic drug monitoring as a tool in treating HIV infection.

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

12 December 2020

Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration

1 reference

12 December 2020

Patient compliance and drug failure in protease inhibitor monotherapy

1 reference

12 December 2020

Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection

1 reference

12 December 2020

Highly active antiretroviral therapy and coronary heart disease: the need for perspective.

1 reference

12 December 2020

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

1 reference

12 December 2020

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function

1 reference

12 December 2020

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin

1 reference

12 December 2020

Population Pharmacokinetic Analysis of Didanosine (2′,3′-Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS-Related Complex

1 reference

12 December 2020

Clinical pharmacokinetics of zidovudine. An update

1 reference

12 December 2020

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

1 reference

12 December 2020

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1 reference

12 December 2020

Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.

1 reference

12 December 2020

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

1 reference

12 December 2020

Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical

1 reference

12 December 2020

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens

1 reference

12 December 2020

A Markov mixed effect regression model for drug compliance

1 reference

12 December 2020

Modeling plasma virus concentration during primary HIV infection

1 reference

12 December 2020

A comparison study of multiple measures of adherence to HIV protease inhibitors.

1 reference

12 December 2020

Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients

1 reference

12 December 2020

3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7)

1 reference

12 December 2020

Zalcitabine population pharmacokinetics: application of radioimmunoassay.

1 reference

12 December 2020

Clinical pharmacokinetics of nucleoside antiretroviral agents

1 reference

12 December 2020

Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis

1 reference

12 December 2020

Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration.

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

1 reference

12 December 2020

Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials

1 reference

12 December 2020

Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens

1 reference

12 December 2020

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

1 reference

12 December 2020

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

1 reference

12 December 2020

Do we need full compliance data for population pharmacokinetic analysis?

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish

1 reference

12 December 2020

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

1 reference

12 December 2020

Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations

1 reference

12 December 2020

A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.

1 reference

12 December 2020

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients

1 reference

12 December 2020

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy

1 reference

12 December 2020

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

1 reference

12 December 2020

Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century

1 reference

12 December 2020

Application of the bootstrap statistical method to the tau-decay-mode problem

1 reference

12 December 2020

Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001

1 reference

12 December 2020

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.

1 reference

12 December 2020

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

12 December 2020

Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir

1 reference

12 December 2020

Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection

1 reference

12 December 2020

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

1 reference

12 December 2020

Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus

1 reference

12 December 2020

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

12 December 2020

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

12 December 2020

Mathematical biology of HIV infections: antigenic variation and diversity threshold

1 reference

12 December 2020

A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Virologic correlates of adherence to antiretroviral medications and therapeutic failure.

1 reference

12 December 2020

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

12 December 2020

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

1 reference

12 December 2020

Editorial: time to end the death trials

1 reference

12 December 2020

Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease

1 reference

12 December 2020

Time from infection with HIV to onset of AIDS in patients with haemophilia in the UK.

1 reference

12 December 2020

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

12 December 2020

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

1 reference

12 December 2020

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

1 reference

12 December 2020

Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics and tolerance of zidovudine in preterm infants

1 reference

12 December 2020

Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period

1 reference

12 December 2020

Critical issues in therapeutic drug monitoring of antiretroviral drugs

1 reference

12 December 2020

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Estimation of HIV dynamic parameters

1 reference

12 December 2020

Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir

1 reference

12 December 2020

Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group

1 reference

12 December 2020

A joint model for nonlinear longitudinal data with informative dropout

1 reference

12 December 2020

Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?

1 reference

12 December 2020

The WHO and why of HIV vaccine trials

1 reference

12 December 2020

Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity.

1 reference

12 December 2020

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.

1 reference

12 December 2020

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

12 December 2020

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

12 December 2020

Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease

1 reference

12 December 2020

Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

1 reference

12 December 2020

Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir

1 reference

12 December 2020

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance

1 reference

12 December 2020

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial

1 reference

12 December 2020

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

1 reference

12 December 2020

Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

12 December 2020

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships

1 reference

12 December 2020

Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

12 December 2020

Pharmacokinetic and other drug interactions in patients with AIDS.

1 reference

12 December 2020

Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.

1 reference

12 December 2020

Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials

1 reference

12 December 2020

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

12 December 2020

Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates

1 reference

12 December 2020

Medication adherence in patients with HIV infection: a comparison of two measurement methods

1 reference

12 December 2020

Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Metabolism of Zidovudine.

1 reference

12 December 2020

Population pharmacokinetic meta-analysis with efavirenz

1 reference

12 December 2020

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex

1 reference

12 December 2020

Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial

1 reference

12 December 2020

The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?

1 reference

12 December 2020

Heterogeneity of HIV-1 and HIV-2.

1 reference

12 December 2020

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

1 reference

12 December 2020

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

1 reference

12 December 2020

Twenty years of therapy for HIV-1 infection.

1 reference

12 December 2020

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

1 reference

12 December 2020

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children

1 reference

12 December 2020

Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials

1 reference

12 December 2020

Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity

1 reference

12 December 2020

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

1 reference

12 December 2020

The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

1 reference

12 December 2020

Drug resistance in patients experiencing early virological failure under a triple combination including indinavir

1 reference

12 December 2020

10.2165/00003088-200544060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference